Semaglutide vs. Tirzepatide: As medical research continues to advance, new treatments for type 2 diabetes & obesity are constantly emerging, and many of these treatments can also have the added benefit of promoting weight loss. Two of the latest treatments to hit the market, semaglutide and tirzepatide. Both are injectable medications that not only help manage blood sugar levels but can also aid in weight loss.

 

The brand names that gained popularity in recent months are: Ozempic, Wegovy, & Mounjaro. The manufacturers have been trying to keep up with the demand but have been effected by shortages. Our programs utilize compounded equivalents made by licensed third party compounding pharmacies.

To learn more about 503A compounded medications and the regulations surrounding them you can visit FDA Compounding Information Website

 

Semaglutide is a GLP-1 receptor agonist that works by mimicking the action of the naturally occurring hormone GLP-1. This hormone helps to regulate blood sugar levels by increasing insulin secretion and slowing down the emptying of the stomach. In clinical trials, semaglutide has been shown to be highly effective in reducing HbA1c levels (a measure of average blood sugar over the past 2-3 months) by up to 1.5%, therefore showing promising weight loss effects. In fact, in one clinical trial, semaglutide was shown to lead to an average weight loss of 15 pounds over 68 weeks.

​

Tirzepatide is a dual GIP and GLP-1 receptor agonist that works by increasing insulin secretion and decreasing glucagon secretion. Therefore leading to a reduction in blood sugar levels and an increase in satiety (feeling of fullness). In clinical trials, researchers have shown that tirzepatide significantly reduces HbA1c levels by up to 2.4%, surpassing other GLP-1 agonist. Additionally, tirzepatide has the potential to promote weight loss. In fact, one clinical trial demonstrated that tirzepatide led to participants achieving an average weight loss of 20 pounds over 52 weeks.

​